CoChat

Liver Resection after Disease Control with Abemaciclib for Solitary Liver Metastasis from Breast Cancer: A Case Report

Open access

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index; 12 of the 21 sources its claims cite were checked for support.

Abstract

INTRODUCTION: Liver metastases from breast cancer are associated with a poorer prognosis than bone or soft tissue metastases. In hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer, endocrine therapy combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has been established as the standard of care. Abemaciclib has demonstrated favorable efficacy in phase III clinical trials and is considered an important option for long-term disease control. With recent advances in systemic therapy, an increasing number of patients achieve sustained disease control; however, prolonged treatment may lead to impaired QOL, financial burden, and the need for long-term therapy. Consequently, the role of local treatment in carefully selected patients with well-controlled disease has increasingly been discussed. Here, we report a case of breast cancer with postoperative recurrent solitary liver metastasis in which disease control was achieved with endocrine therapy plus abemaciclib, followed by liver resection, resulting in long-term recurrence-free survival. CASE PRESENTATION: A 45-year-old woman with HR-positive, HER2-negative breast cancer underwent breast-conserving surgery followed by adjuvant chemotherapy, radiotherapy, and endocrine therapy. Five years after surgery, follow-up CT revealed a solitary liver lesion. Percutaneous biopsy demonstrated adenocarcinoma consistent with a solitary liver metastasis from breast cancer. Combination therapy with a luteinizing hormone-releasing hormone agonist, fulvestrant, and abemaciclib was initiated. Although dose reduction of abemaciclib was required because of grade 3 neutropenia, stable disease was maintained for approximately 1 year. Given the sustained disease control, absence of extrahepatic metastasis, and the patient's strong preference, laparoscopic liver resection was performed after obtaining informed consent. Pathological examination revealed adenocarcinoma consistent with metastatic breast cancer, with negative surgical margins. Postoperatively, endocrine therapy alone was continued, and the patient has remained recurrence-free for 3 years after liver resection. CONCLUSIONS: This case represents a rare report of surgical resection for breast cancer liver metastasis after CDK4/6 inhibitor-based therapy. It suggests that local treatment may be effective even in cases with suspected endocrine-resistant disease and provides practical insight into patient selection and treatment strategies, as the case fulfilled previously reported criteria for local therapy.

Overview

CoChat Summary

## TL;DR

This case report describes a 45-year-old woman with HR-positive, HER2-negative breast cancer who developed a solitary liver metastasis, achieved about 1 year of stable disease on fulvestrant plus abemaciclib, and then underwent laparoscopic liver resection. She remained recurrence-free for 3 years after surgery, suggesting local treatment may be an option in carefully selected patients with well-controlled disease.

## Key findings

  • A solitary liver lesion measuring 28.5 mm was found 5 years after breast-conserving surgery; biopsy confirmed metastatic breast cancer.
  • With luteinizing hormone–releasing hormone agonist + fulvestrant + abemaciclib, the liver lesion remained stable for approximately 1 year by RECIST 1.1, despite grade 3 neutropenia requiring abemaciclib dose reduction from 300 to 100 mg/day.
  • After laparoscopic posterior sectionectomy with cholecystectomy, pathology showed metastatic adenocarcinoma with negative margins and the patient has remained recurrence-free for 3 years after liver resection.
  • The authors note that in phase III trials of abemaciclib, median progression-free survival was 29.0 months and median overall survival was 66.8 months when used first-line, and they compare the patient’s recurrence-free interval of 4 years from abemaciclib initiation with these trial outcomes.

## Methods

  • Design: Single-patient case report.
  • Data/sample: One 45-year-old woman with HR-positive, HER2-negative breast cancer and a solitary liver metastasis.
  • Main analysis: Clinical course tracked with CT, FDG-PET/CT, biopsy, immunohistochemistry, tumor markers, and response assessment using RECIST 1.1; pathology after resection confirmed metastatic breast cancer and margin status.

## Limitations

  • The paper is a single case report, so the text itself only supports an anecdotal conclusion and does not establish general effectiveness.
  • The authors state that evidence for liver resection in this setting comes from non-randomized retrospective studies and is subject to selection bias and heterogeneity.
  • The report does not provide comparative data against non-surgical management in similar patients; this is evident from the text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.70352/scrj.cr.26-0141

Cites

23 of 24 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Immunohistochemical findings of the primary breast tumor and liver metastasis. (A–D) Primary tumor: ER (>90%), PgR (>90%), HER2-IHC 0, and Ki-67 index (18%). (E–G) Liver metastasis: ER (>90%), PgR (5%–10%), and CK7 (positive). HER2-IHC 0 and Ki-67 (<1%) of the metastatic lesion were assessed, but corresponding images were not available. CK7, cytokeratin 7; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PgR, progesterone receptor
Fig. 1 Immunohistochemical findings of the primary breast tumor and liver metastasis. (A–D) Primary tumor: ER (>90%), PgR (>90%), HER2-IHC 0, and Ki-67 index (18%). (E–G) Liver metastasis: ER (>90%), PgR (5%–10%), and CK7 (positive). HER2-IHC 0 and Ki-67 (<1%) of the metastatic lesion were assessed, but corresponding images were not available. CK7, cytokeratin 7; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PgR, progesterone receptorCC BY · PubMed Central
Fig. 2 Contrast-enhanced CT and FDG-PET/CT images of the liver metastasis. The yellow arrows indicate the liver metastasis. (A) Arterial phase image at recurrence demonstrating a hyperenhancing lesion in segments 5 and 6 of the liver. (B) Delayed phase image showing relative hypoattenuation with peripheral enhancement. (C) Arterial phase image obtained after approximately 1 year of systemic therapy, demonstrating tumor shrinkage and reduced enhancement. (D) Delayed phase image after systemic therapy showing decreased lesion conspicuity compared with pretreatment imaging. (E) FDG-PET/CT image obtained after approximately 1 year of systemic therapy, demonstrating FDG uptake corresponding to the liver lesion (SUVmax: early 4.5, delayed 5.5). (F) MIP image showing no evidence of extrahepatic metastases; mild uptake in the right palm was considered physiological. At recurrence, the longest diameter of the liver metastasis was 28.5 mm. After approximately 1 year of systemic therapy, the lesion decreased in size to a longest diameter of 21.8 mm, corresponding to a tumor size reduction of 23.5% and classified as stable disease according to RECIST version 1.1. In both the recurrent and post-treatment (preoperative) images, the lesion demonstrated arterial phase hyperenhancement followed by relative washout in the delayed phase. FDG, fluorodeoxyglucose; MIP, maximum intensity projection; RECIST, Response Evaluation Criteria in Solid Tumors; SUVmax, maximum standardized uptake value
Fig. 2 Contrast-enhanced CT and FDG-PET/CT images of the liver metastasis. The yellow arrows indicate the liver metastasis. (A) Arterial phase image at recurrence demonstrating a hyperenhancing lesion in segments 5 and 6 of the liver. (B) Delayed phase image showing relative hypoattenuation with peripheral enhancement. (C) Arterial phase image obtained after approximately 1 year of systemic therapy, demonstrating tumor shrinkage and reduced enhancement. (D) Delayed phase image after systemic therapy showing decreased lesion conspicuity compared with pretreatment imaging. (E) FDG-PET/CT image obtained after approximately 1 year of systemic therapy, demonstrating FDG uptake corresponding to the liver lesion (SUVmax: early 4.5, delayed 5.5). (F) MIP image showing no evidence of extrahepatic metastases; mild uptake in the right palm was considered physiological. At recurrence, the longest diameter of the liver metastasis was 28.5 mm. After approximately 1 year of systemic therapy, the lesion decreased in size to a longest diameter of 21.8 mm, corresponding to a tumor size reduction of 23.5% and classified as stable disease according to RECIST version 1.1. In both the recurrent and post-treatment (preoperative) images, the lesion demonstrated arterial phase hyperenhancement followed by relative washout in the delayed phase. FDG, fluorodeoxyglucose; MIP, maximum intensity projection; RECIST, Response Evaluation Criteria in Solid Tumors; SUVmax, maximum standardized uptake valueCC BY · PubMed Central
Fig. 3 Pathological findings of the resected liver metastasis. (A) Macroscopic appearance of the resected specimen showing a whitish solid tumor measuring 18 × 17 mm (arrow). (B) H&E-stained section demonstrating the overall architecture of the tumor with negative surgical margins. Only minimal fibrosis was observed in the non-tumorous background liver tissue. (C) H&E-stained section at low magnification (×4) revealing proliferation of atypical epithelial cells with mildly pleomorphic, round-to-oval nuclei forming small tubular, fused tubular, and cribriform structures, consistent with adenocarcinoma. No evident necrosis or fibrosis was observed in the tumor. H&E, hematoxylin and eosin
Fig. 3 Pathological findings of the resected liver metastasis. (A) Macroscopic appearance of the resected specimen showing a whitish solid tumor measuring 18 × 17 mm (arrow). (B) H&E-stained section demonstrating the overall architecture of the tumor with negative surgical margins. Only minimal fibrosis was observed in the non-tumorous background liver tissue. (C) H&E-stained section at low magnification (×4) revealing proliferation of atypical epithelial cells with mildly pleomorphic, round-to-oval nuclei forming small tubular, fused tubular, and cribriform structures, consistent with adenocarcinoma. No evident necrosis or fibrosis was observed in the tumor. H&E, hematoxylin and eosinCC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 0 Not valid · 6 Not checked · 13 Own results and interpretations

7 more claims

Create a free account to see all 28 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Citations

Cites

Metadata

Authors
Kurokawa, Y., Terakawa, H., Mohri, R., Hirata, M., Gabata, R., Yagi, S., & Inaki, N.
Affiliations
Kanazawa University Hospital (JP)
Corresponding author
Kurokawa, Yuki
Venue
Surgical case reports
Published
2026
Volume
12
Issue
1
Pages
n/a
ISSN
2198-7793 (ISSN-L)
OpenAlex
W7163542200
Cited by
0
References
23
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Surgical Case Reports (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Metastasis and carcinoma case studies
Keywords
breast cancer, liver metastasis, abemaciclib, CDK4/6 inhibitors, endocrine therapy, fulvestrant, laparoscopic liver resection, hormone receptor-positive HER2-negative breast cancer, recurrence-free survival, neutropenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.